Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. anaphylaxis
Show results for
Products
Services
Training
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Anaphylaxis Articles & Analysis

20 news found

Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy

Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy

Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...

ByIntrommune Therapeutics


VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures

Important Safety Information (ISI) Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio. ...

ByVBI Vaccines Inc.


Possible Side Effects of Local Anesthesia

Possible Side Effects of Local Anesthesia

Allergic reactions: Urticaria and anaphylaxis in rare cases, also referred to as ‘immediately hypersensitive’ due a fast, strong reaction to the local anesthetic. ...

ByMilestone Scientific, Inc.


Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri

Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri

Important Safety Information (ISI) Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio. ...

ByVBI Vaccines Inc.


VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer

Important Safety Information (ISI) Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio. ...

ByVBI Vaccines Inc.


VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022

Important Safety Information (ISI) Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio. ...

ByVBI Vaccines Inc.


Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 ...

ByIntrommune Therapeutics


Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. “Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant ...

ByIntrommune Therapeutics


VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022

Important Safety Information (ISI) Do not administer PreHevbrio to individuals with a history of severe allergic reaction (e.g. anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of PreHevbrio. ...

ByVBI Vaccines Inc.


The Essential Guide to Food Allergies

The Essential Guide to Food Allergies

The IgE-mediated allergies include food allergy manifested as angioedema, nausea, abdominal pain, anaphylaxis including wheat dependent exercise-induced anaphylaxis, respiratory allergy as well as skin allergy. ...

ByHYCOR Biomedical


INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose

NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose ...

ByIntrommune Therapeutics


Blue Earth Diagnostics Highlights Axumin (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

Blue Earth Diagnostics Highlights Axumin (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)

Hypersensitivity reactions, including anaphylaxis, may occur in patients who receive Axumin. Emergency resuscitation equipment and personnel should be immediately available. ...

ByBlue Earth Diagnostics


Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen

Serious hypersensitivity reactions, including anaphylaxis, may be due to dimethyl sulfoxide (DMSO) in ABECMA. Infections: ABECMA should not be administered to patients with active infections or inflammatory disorders. ...

ByBristol Myers Squibb Corporate


Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships

Targeted delivery of medication is expected to decrease the rate of side effects linked to swallowing food allergy proteins, including eosinophilic esophagitis, gastrointestinal discomfort and potentially life-threatening anaphylaxis that requires the use of emergency epinephrine. ...

ByIntrommune Therapeutics


Intrommune Therapeutics Launches #PeanutAllergyStrong

Intrommune Therapeutics Launches #PeanutAllergyStrong

Targeted delivery of medication is expected to decrease the rate of side effects linked to swallowing food allergy proteins, including eosinophilic esophagitis, gastrointestinal discomfort and potentially life-threatening anaphylaxis that requires the use of emergency epinephrine. ...

ByIntrommune Therapeutics


Intrommune Therapeutics to Present at BIO Digital 2021

Intrommune Therapeutics to Present at BIO Digital 2021

NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. The event will be live June 10-11 & 14-18, 2021. Michael Nelson, JD, Co-Founder and CEO will provide an overview of ...

ByIntrommune Therapeutics


FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat

FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat

In severe cases the allergy can cause anaphylaxis which can be potentially fatal. The condition can appear in patients who have tolerated meat for many years, with researchers believing that sensitization to alpha-Gal may be the result of a bite from the lone star tick (Amblyomma americanum). ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings

New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings

According to the American College of Allergy, Asthma and Immunology, there are between 90 to 100 deaths per year caused by insect sting anaphylaxis. Stinging Insect allergy is one of the allergies most frequently associated with anaphylaxis in both adults and children. ...

ByThermo Fisher Scientific, LIMS & Laboratory Software


TargetSolutions’ EMS Continuing Education Course Examines Emergency Care for Allergies and Anaphylaxis

TargetSolutions’ EMS Continuing Education Course Examines Emergency Care for Allergies and Anaphylaxis

TargetSolutions’ EMS Allergies and Anaphylaxis Basic training course covers the topics of allergy-related incidents and the appropriate care needed in such situations. ...

ByTargetSolutions


Shimadzu’s New Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis of Sub-Visible Particles

Shimadzu’s New Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis of Sub-Visible Particles

These aggregates can induce allergic systemic reactions, such as anaphylaxis and other severe side effects if they make their way into the final product. ...

ByShimadzu Scientific Instruments Inc

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT